Endocrine Abstracts

Background: In the UK, 1 to 4 per 1000 people have primary hyperparathyroidism (PHPT) and are at risk of hypercalcaemia and its complications. Whilst surgery is the only curative option in the management of PHPT, several patients are managed conservatively or medically. Cinacalcet (a calcimimetic) has a role in PHPT management, in those who have declined or are unable to progress to surgery. It is important that the use of Cinacalcet in these cases adheres to ...